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Abstract
This work reviews dementia policy in the UK using the Prime Minister’s Dementia Challenge 2020 Imple-
mentation Plan and the Phase 1 Review of the plan provided by the Department of Health and Social Care
(DHSC). The proposed Implementation Plan is aimed at making the UK the best country in the world for
dementia care and research. In order to achieve this goal, the plan concentrates on the four key aspects of
the new dementia policy, which are risk reduction, health and care, awareness and social action, and research.
This policy report is based on data provided by the DHSC and Alzheimer’s Research UK (ARUK). Here, the
Implementation Plan and the Phase 1 Review are compared to illustrate the progress achieved so far, as well as
to suggest recommendations. Whilst the commitments of the plan have been partially achieved, improvement
is still required, including but not limited to improved risk awareness and patent protection policies.
Science ⇒ Policy
The article illustrates several weak points in UK dementia policy which should be addressed to tackle the
dementia problem in the country. Policymakers should devote more attention to the participation in clinical
trials, the engagement of minority groups, risk factors and develop more accurate metrics. Suggested options
include stronger patent protection, the greater role of Informed Consent, better inclusion, and others. The
proposed measures are expected to improve the existing anti-dementia policy in the UK.
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Dementia Problem in the
United Kingdom
The World Health Organisation (WHO) defines
dementia as a progressive syndrome which causes
deterioration in cognitive function [1]. It af-
fects memory, thinking, orientation, comprehen-
sion, calculation, learning capacity, language, and
judgement. However, consciousness is not af-
fected. “The impairment in cognitive function
is commonly accompanied, and occasionally pre-
ceded, by deterioration in emotional control, so-
cial behaviour, or motivation” [1]. According
to Alzheimer’s Research UK (ARUK) Demen-
tia Statistics Hub, 885,000 people in the UK live
with dementia, of which 127,000 have mild demen-
tia, 246,000 have moderate dementia and 511,000
have severe dementia [2].
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However, due to poor public awareness, only
474,693 people were diagnosed with dementia
by their GPs [3]. The current cost of dementia
in the UK is £26 billion, and it is expected to
more than double by 2040, reaching the sum of
£55 billion [4] As for the number of people with
dementia, figure 1 shows that it will also grow
rapidly and is expected to be more than 2 million
people by 2050 [4].
One of the key factors contributing to dementia
growth in the UK is increasing life expectancy,
because age is the primary risk factor for demen-
tia alongside other risk factors including diabetes
and cardiovascular diseases. Dementia is now one
of the main causes of death in the UK: in 2017,
13% of the total population of the UK died due
to dementia, which prevailed over other causes
of death like ischaemic heart and cerebrovascular
diseases [4].Figure 2 shows the increase in deaths
caused by dementia from 2005 to 2017 [4].
Moreover, by 2040 deaths due to dementia are
estimated to exceed those as a result of cancer
in the UK [4]. According to a 2017 Ipsos MORI
Health, Ageing and Support Survey, 52% of peo-
ple thought that dementia was the biggest health
problem facing older people [5].
Dementia Policy Implementa-
tion Plan: Findings from Phase
1 Review
The primary aim of the Implementation Plan,
which was published on 6th March 2016, was
to provide a useful framework to develop high
quality, fully integrated dementia health and care
services that are aligned with the commitments
in the Prime Minister’s Challenge on Dementia
2020. This Challenge aimed to make England, by
2020, the best country in the world for dementia
care, support, research and awareness [6]. In 2019,
the Government published the Phase 1 Review
to assess the progress of the new policy. This was
especially important because Brexit negotiations
are likely to have an impact on the research in-
dustry; leaving the European Union could result
in losing financial support for research, some Eu-
ropean researchers, and participation in clinical
trials, although it is not possible to estimate such
an impact yet [7].
The Plan includes four key aspects:
1. risk reduction
2. health and care delivery
3. awareness and social action
4. research
Risk Reduction
Dementia risk indicators were developed to pro-
vide local authorities with an understanding of
dementia risk level in their local populations.
The Medical Research Council, supported by
the Welcome Trust, invested £34 million in the
UK Biobank to carry out a clinical study on
100,000 participants, which is expected to create
the largest dataset in the world about dementia
risk factors [6]. These actions are expected to
delay the prevalence of dementia in the popula-
tion as well as inform people at high risk how
to reduce it. The plan does not include the list
of particular risk factors which should be taken
into account. Although, existing research pro-
vides sufficient evidence on risk factors such as
cardiovascular diseases, obesity, smoking, lower
level of education and diabetes, which could be
included in the plan [8–11]. Despite the fact that
some guidance on risk factors was provided to the
public as a part of the “One You” NHS campaign,
certain social groups including Black and Minor-
ity Ethnic (BAME) and non-English speakers are
not included in the information programme [7].
Health and Care
The Department of Health and Social Care
(DHSC) has published a declaration on post-
diagnostic care and support [12]. This document
introduces the collaboration of the Government,
patients and non-governmental organisations like
Alzheimer’s Society, Dementia UK and others,
which provides support for families and raises
funds to help people living with dementia. GPs
are now responsible for the development and re-
alisation of personalised care plans for dementia
patients. They are working in tight collaboration
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Figure 1: Number of people living with dementia, 2019 (Source: Alzheimer’s Research UK, 2021)
Figure 2: Deaths caused by dementia (Source: Alzheimer’s Research UK, 2021)
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with memory assessment services and care insti-
tutions to better develop personalised care plans
which provide patients, healthcare professionals
and carers with a clear vision of their treatment.
The Phase 1 Review concludes that health and
care commitment has been partially met nation-
ally, but the diagnosis rate across the country
is inconsistent – current diagnosis metrics need
improvement [7].
Awareness and Social Action
The Awareness and Social Action programme in-
cludes three main commitments. The first one
is the creation of Dementia Friends, a volunteer
network, responsible for raising awareness of the
dementia problem in society. They run informa-
tion sessions in their communities and provide
care to local people diagnosed with dementia
[13]. Although the number of Dementia Friends
only reached 3 million out of its initial 4 million
target, it was still concluded that the primary
aim of raising social awareness was achieved by
the Government [7]. Local and central govern-
ments also participate in the programme. The
civil service Dementia Friends programme trained
around 35,000 Dementia Friends [7]. Secondly,
the plan promoted Dementia Friendly Commu-
nities (DFCs) run by ARUK, which contributed
to inclusion and improving the quality of life for
people with dementia by the creation of Memory
Cafés, where patients with dementia can meet
health professionals and members of local com-
munity, and by the use of social media platforms
for information campaigns and news sharing. In
2019, 346 areas signed up to be DFCs – this is two
times more than in 2016 [7]. A third programme
mentioned in the plan is Dementia Friendly Busi-
nesses. By 2018, more than 11,000 organisations
committed to be Dementia Friendly, which in-
cludes supporting staff affected by dementia as
well as clients with dementia [7]. According to the
Dementia Friendly Awards 2019, HSBC UK was
recognised as the Dementia Friendly Organisation
of the Year.
Overall, all these three commitments were esti-
mated to have a positive influence [7]. However,
the Phase 1 Review criticised the plan for exclud-
ing ethnic minorities and non-English speakers
from the awareness programme and recommended
to engage these groups [7].
Research
The research commitments of the Implementation
Plan include increased investment in dementia
research and obtaining a greater number of partic-
ipants in clinical trials for prospective dementia
treatments. This is necessary for the creation
of the Join Dementia Research database, a ser-
vice which allows people to register their inter-
est in participating in dementia research and be
matched to suitable studies. The Government
invests £60 million per year in dementia research;
this is twice as much as it was investing before
the Implementation Plan [6, 7]. In addition, the
UK Dementia Research Institute acquired a total
sum of £290 million from ARUK and other NGOs
[7]. Also, ARUK is trying to encourage more aca-
demics to focus their research on dementia by
delivering research funding and creating the Drug
Discover Alliance. This is expected to attract spe-
cialists to the problem as well as getting patients
to participate in clinical trials. Current treatment
trials are expected to provide results by 2025. Ac-
cording to The Trajectory of Dementia in the UK
report, if new treatment slows the progression of
dementia by 25%, by 2050 there will be 6% fewer
people who suffer from severe forms of dementia
[14]. However, there are goals which have not
been achieved yet – only 1% out of an expected
25% joined the Join Dementia Research database
[6, 7].
The plan also includes the creation of the Demen-
tia Discovery Fund (DDF) – a venture capital
fund aimed at boosting dementia research; in-
vestors are leading pharmaceutical companies,
NGOs and the Government, which altogether
have committed more than $100 million to the
fund [6]. The Phase 1 Review does not include
any information on the fund’s performance.
Future Directions
According to the Phase 1 Review, the Implemen-
tation Plan has partially achieved its goals in
some areas but still has space for improvement [7].
In particular, the plan ignores minority groups
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such as ethnic minorities, non-English speakers,
and people with mental and physical health chal-
lenges, who must be included in the risk reduction
and awareness programmes [7]. Also, the plan
does not specify the risk factors of dementia. In-
cluding such factors could contribute to a risk
reduction programme by raising awareness of po-
tential causes of dementia [8–11]. It is crucial
that the scope of risk factors is not limited to
only health issues like smoking or obesity. Other
factors should also be taken into account. Ex-
isting analysis shows that education also plays a
role dementia prevention [15]. According to the
Phase 1 Review, the number of people partici-
pating in clinical trials is smaller than expected
– only 1% of dementia patients instead of 25%
[7]. Including information about clinical trials of
prospective treatment into the awareness materi-
als could help to improve the participation rate.
Also, the informed consent document could be
made in a way which emphasises the benefits of
free dementia treatment for the subjects – this
could possibly contribute to the research goal.
The Implementation Plan concentrates exclu-
sively on developing treatment options, whereas
it could also emphasise the improvement of the
existing methods of treatment. In particular, it
is crucial to devote attention to a combination
treatment of donepezil and memantine, since this
is considered to be the most effective patient
prescription plan today [16]. The affordability
of dementia treatment could be improved if the
Government invested more in cheaper generic
copies of memantine and donepezil - the patents
on which have already expired, and formula is
available - because a memantine and donepezil
course is usually prescribed for long-term treat-
ment. Affordable drugs could counterbalance the
financial burden of carers [17]. Despite the fact
that the plan sets the ambitious goal of “making
the UK the best country for people with demen-
tia”, it does not include any changes in the exist-
ing regulation [6]. The plan should propose the
longer patent protection of prospective dementia
drugs. Being the strongest stimulator for socially
valuable research, longer and broader patents
are likely to nudge pharmaceutical companies to
switch from just financing the DDF to conduct-
ing R&D themselves to obtain the dementia drug
market share [18, 19].
© 2021 The Author(s). Published by the Cambridge
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